MedTrace Logo

PK Analysis of Moxifloxacin in the Treatment of CAP

NCT01983839 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2015-04-06

Study results available
· View outcomes & findings →

Summary

At the Department of Infectious Diseases, Aarhus Denmark, moxifloxacin is used in the empirical treatment of severe community-acquired pneumonia (CAP). This study was designed to determine the pharmacokinetics of moxifloxacin 400 mg/day to patients treated empirically for CAP. To accomplish this aim, we established a pharmacokinetic population model. This approach was adopted with the dual purpose of assessing the potential efficacy of the drug and performing Monte-Carlo simulations to characterize the maximal MICs for which recommended pharmacokinetic-pharmacodynamic (PK-PD) targets are obtained for pathogens commonly known to cause CAP.

Conditions

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Eskild Petersen, MD, Assoc. Prof., D.Sc. · Department of Infectious Diseases, Aarhus University Hospital, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01983839 on ClinicalTrials.gov